TNXP Tonix Pharmaceuticals Holding Corp.

8-K Current Report

Filed: March 3, 2026

Health Care

Pharmaceutical Preparations

Tonix Pharmaceuticals Holding Corp. Overview

Tonix Pharmaceuticals Holding Corp. (TNXP) 8-K current report filed with SEC EDGAR on March 3, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events

AI Filing Analysis
8-K

Item 7.01 · Regulation FD Disclosure

• Reg FD Item 7.01 filing contains only liability disclaimer language; no material business, financial, or operational information disclosed

Item 8.01 · Other Events

• Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market, effective March 3, 2026
• Global Select Market is Nasdaq's highest tier, signaling stronger institutional eligibility and broader index inclusion potential

+1 more insights

Other Tonix Pharmaceuticals Holding Corp. 8-K Filings

8-K Mar 18, 2026

8-K Mar 13, 2026

8-K Mar 10, 2026

Get deeper insights on Tonix Pharmaceuticals Holding Corp.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.